CompletedPhase 2

Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection

82 participantsStarted 2010-10

Plain-language summary

A Phase IIa Exploratory, Open label, Single Dose Regimen, Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and Pharmacokinetics of OZ439 in adult patients with acute, uncomplicated Plasmodium falciparum or vivax malaria mono-infection.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female patients between the age of 18 and 60 years, inclusive
✓. Body weight between 40 kg and 90 kg inclusive
✓. Presence of mono-infection of P. falciparum or P. vivax confirmed by:
✓. Written informed consent, in accordance with local practice, provided by patient. If the patient is unable to write, witnessed consent is permitted according to local ethical considerations
✓. Ability to swallow oral medication
✓. Ability and willingness to participate and access the health facility
✓. Agree to minimum of 4 days hospitalisation for drug administration and pharmacokinetic sampling

Exclusion criteria

✕. Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organisation Criteria 2010 (Attachment 2)
✕. Mixed Plasmodium infection
✕. Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3 or more watery stools per day
✕. Presence of other serious or chronic clinical condition requiring hospitalisation.
✕. Severe malnutrition (defined as the weight-for-height being below -3 standard deviation or less than 70% of median of the NCHS/WHO normalised reference values).
✕. Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval greater than or equal to 450 msec), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or other abnormality (including head trauma).
✕. Known history of hypersensitivity, allergic or adverse reactions to artemisinin containing compounds or mefloquine or drug in the national guidelines for P. vivax.
✕. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).

What they're measuring

Derived Parasite Reduction Rate at 24 Hours (PPR24)

Timeframe: 24 hours after study drug administration

Trial details

NCT IDNCT01213966

SponsorMedicines for Malaria Venture

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-05

Results submitted2013-07-22

View on ClinicalTrials.gov More Malaria, Falciparum trials